Welcome to our dedicated page for KYNTRA BIO SEC filings (Ticker: KYNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio filings document the company's public-company governance, financial reporting, clinical-development updates, and Nasdaq listing matters. Recent 8-K reports cover results of operations and financial condition, including business updates tied to FG-3246, roxadustat, and the FG-3180 biomarker program.
The filing record also includes definitive proxy statements that disclose governance matters, executive compensation, equity awards, and shareholder voting information. Additional 8-K disclosure addresses Nasdaq continued-listing compliance, reflecting the company's capital-market and reporting obligations as a Nasdaq-listed biopharmaceutical issuer.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.